Cellestia is pioneering medical research by developing innovative therapeutics with new modes of action. Cellestia is developing first-in-class therapies to control pathogenic gene expression by selective inhibition of previously undruggable transcription factors in the cell nucleus.  The company’s clinical lead, CB-103, has advanced to phase 2 in oncology, followed by a rich R&D pipeline of novel gene transcription factor inhibitors in oncology, auto-immune and inflammatory disorders

Research description

• In-house research to support clinical development of lead candidate in oncology and non-oncology indication.
• Targeting novel “undruggable” transcription factors.
• Support pipeline expansion based on in-house research.